eligibility_summary
Eligible patients: enrolled in the Canadian avelumab 1LM PSP, histologically confirmed stage IV LA/mUC, no progression after 1L platinum chemo, received avelumab 1LM after 1L platinum, last chemo ≤10 weeks before PSP entry, ECOG 0–1, ≥6 months follow-up from avelumab start or death with known date. Exclude: PSP enrollees who didn’t get avelumab, pregnancy at index, or participation in any interventional trial. Index date: avelumab 1LM initiation post-1L platinum.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Avelumab first-line maintenance (10 mg/kg IV every 2 weeks) after 4–6 cycles of platinum chemotherapy in locally advanced/metastatic urothelial carcinoma. Type/mechanism: Human IgG1 monoclonal antibody immune checkpoint inhibitor that binds PD-L1, blocking PD-L1 interactions with PD-1 and B7.1 to restore T-cell antitumor activity, its intact Fc enables antibody-dependent cellular cytotoxicity (ADCC). Targets: PD-L1 on tumor and immune cells, the PD-1 signaling pathway on T cells, engages NK cells via Fcγ receptors. Observational Canadian study, terminated for strategic reasons.